GreensKeeper Asset Management released its Q2 2025 investor letter, revealing a 3.6% decline in the Value Fund net of fees and expenses. The US dollar’s depreciation negatively impacted performance by over 5.0% YTD. Check out the fund’s top 5 holdings for potential investment insights for 2025.

Novo Nordisk A/S (NYSE:NVO) was highlighted in GreensKeeper Asset Management’s Q2 2025 investor letter. The stock saw a one-month return of -17.42% and lost 57.89% over the last 52 weeks. With a market capitalization of $246.974 billion, NVO closed at $56.98 per share on August 22, 2025.

Burke Wealth Management added Novo Nordisk A/S (NYSE:NVO) to its portfolio in Q2 2025, citing the company’s leading position in the insulin market. Despite competition from Eli Lilly, Burke believes NVO’s GLP-1 franchise holds value and is undervalued by the market.

Novo Nordisk A/S (NYSE:NVO) is not among the 30 most popular stocks among hedge funds, with 45 portfolios holding the stock at the end of Q2 2025. While NVO shows investment potential, certain AI stocks may offer greater upside with less downside risk. Explore undervalued AI stocks in our free report for potential investment opportunities.

Read more at Yahoo Finance: Here’s Why GreensKeeper Asset Management Added Novo Nordisk (NVO) to Its Portfolio